Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chenggong Li

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
The Lancet. Haematology|July 26, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?Chenggong Li, Heng Mei
Briefings in Functional Genomics|January 18, 2020
Applications and explorations of CRISPR/Cas9 in CAR T-cell therapyChenggong Li, Heng Mei, Yu Hu
Journal of Hematology & Oncology|May 6, 2024
Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meetingYun Kang, Chenggong Li, Heng Mei
Experimental Hematology & Oncology|October 11, 2023
Targeting CD22 for B-cell hematologic malignanciesJia Xu, Wenjing Luo, Chenggong Li, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|May 31, 2017
Global Regulation of Differential Gene Expression by c-Abl/Arg Oncogenic KinasesQincai Dong, Chenggong Li, Xiuhua Qu, et al.
Therapeutic Advances in Hematology|May 9, 2024
Treatment of multiple myeloma: What is the impact on T-cell function?Chenggong Li, Xindi Wang, Jia Xu, et al.
Translational Cancer Research|May 25, 2026
Physical activity and cancer survival: the role of peripheral blood immune and inflammatory markers in reducing mortality-a retrospective cohort study based on NHANES 1999-2018Xin Liu, Xuefei Fan, Chenggong Li, et al.
Frontiers in Immunology|July 5, 2022
Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple MyelomaMengyi Du, Linlin Huang, Haiming Kou, et al.
Peerj|July 5, 2022
Therapeutic targets and signaling pathways of active components of QiLing decoction against castration-resistant prostate cancer based on network pharmacologyHongwen Cao, Dan Wang, Renjie Gao, et al.
Frontiers in Immunology|May 28, 2026
Induction immunochemotherapy followed by concurrent chemoradiotherapy improves survival in unresectable esophageal cancer: a systematic review, meta-analysis, and network meta-analysisXuefei Fan, Xin Liu, Song Mi, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
The Lancet. Haematology|July 26, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?Chenggong Li, Heng Mei
Briefings in Functional Genomics|January 18, 2020
Applications and explorations of CRISPR/Cas9 in CAR T-cell therapyChenggong Li, Heng Mei, Yu Hu
Journal of Hematology & Oncology|May 6, 2024
Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meetingYun Kang, Chenggong Li, Heng Mei
Experimental Hematology & Oncology|October 11, 2023
Targeting CD22 for B-cell hematologic malignanciesJia Xu, Wenjing Luo, Chenggong Li, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|May 31, 2017
Global Regulation of Differential Gene Expression by c-Abl/Arg Oncogenic KinasesQincai Dong, Chenggong Li, Xiuhua Qu, et al.
Therapeutic Advances in Hematology|May 9, 2024
Treatment of multiple myeloma: What is the impact on T-cell function?Chenggong Li, Xindi Wang, Jia Xu, et al.
Translational Cancer Research|May 25, 2026
Physical activity and cancer survival: the role of peripheral blood immune and inflammatory markers in reducing mortality-a retrospective cohort study based on NHANES 1999-2018Xin Liu, Xuefei Fan, Chenggong Li, et al.
Frontiers in Immunology|July 5, 2022
Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple MyelomaMengyi Du, Linlin Huang, Haiming Kou, et al.
Peerj|July 5, 2022
Therapeutic targets and signaling pathways of active components of QiLing decoction against castration-resistant prostate cancer based on network pharmacologyHongwen Cao, Dan Wang, Renjie Gao, et al.
Frontiers in Immunology|May 28, 2026
Induction immunochemotherapy followed by concurrent chemoradiotherapy improves survival in unresectable esophageal cancer: a systematic review, meta-analysis, and network meta-analysisXuefei Fan, Xin Liu, Song Mi, et al.
Pageof 3